Abstract. The aim of the present study was to predict the prognostic value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the metastatic lymph nodes (mLNs) of patients with papillary thyroid carcinoma (PTC) with a negative iodine-131 ( 131
Introduction
Papillary thyroid carcinoma (PTC) is the most common type of thyroid tumor and despite developments in imaging techniques, the incidence rate of PTC has increased over the last decade (1) . Locoregional lymph node (LN) metastasis is typically one of the first steps in the progression of PTC to distant metastasis from the thyroid (2, 3) . According to a previous report from the National Comprehensive Cancer Network, the LN metastasis rate in PTC is 50-80% (4).
The most effective therapeutic strategies for well-differentiated thyroid carcinoma are thyroid surgery and iodine-131 ( 131 I) radiotherapy (5) . 131 I radiotherapy is not only appropriate for primary tumors but also for LN and distant metastasis (6) . Kim et al (7) reported that for lesions with high serum thyroglobulin (Tg), a negative cervical sonography and an 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan exhibit limited therapeutic effect with 131 I therapy. Positron emission tomography and computed tomography (PET/CT) has been applied for the evaluation and monitoring of PTC and nodal metastasis, particularly for patients with elevated serum Tg levels but produced negative findings with an iodine-131 ( 131 I) whole-body scan (WBS) (8) . Previously, small LNs have been detected with PET/CT, which are easily misdiagnosed by 131 I-WBS due to a low resolution and the presence of remnant thyroid tissue (9) . To the best of our knowledge, the association between metastatic LNs (mLNs) and the effect of 131 I therapy has not yet been reported. The aim of the present retrospective study was to evaluate the clinical efficiency of 18 F-FDG PET/CT in predicting the therapeutic response of mLNs in patients with PTC following Jiaotong University School of Medicine and the requirement for informed consent was waived. Between January 2012 and August 2017, 106 patients at the Nuclear Medicine Department of Xinhua Hospital Affiliated with The Shanghai Jiaotong University School of Medicine (Shanghai, China) were assessed based on the following criteria: i) All patients underwent a near-total or a total thyroidectomy; ii) patients received a PET/CT examination prior to their first and following their second or later 131 I radioiodine ablation treatment; iii) patients with LN metastasis were identified by fine-needle aspiration biopsy (FNAB), postoperative pathology and other clinical methods, including neck ultrasonography, CT, 131 I-WBS, and serum Tg and thyroglobulin-antibody levels. Patients were excluded if they had a history or coexistence of other metastasis, including lung or bone metastasis. In addition, patients were excluded if the LNs were not confirmed by pathology, biopsy or other clinical findings. In total, 74 patients were excluded, including 16 patients with bone metastasis, 35 patients with lung metastasis and 23 patients who did not possess appropriate evidence of LN metastasis. Therefore, 18 female and 14 male patients were enrolled in the present study.
mLNs. The mLNs involved in the present study were included according to the following criteria: i) The mLN was diagnosed by postoperative pathology or FNAB; ii) the LN had a positive 131 I accumulation on the 131 I WBS; iii) ultrasonographic features of malignant thyroid nodules included hypoechoic lesions, a longitudinal/transverse ratio <2, a blurred or spicular margin, microlobular contour, single or multiple microcalcifications, both internal and peripheral flow, and extrathyroidal extension or an interrupted and discontinuous echogenicity of a capsule (10); iv) a mLN on CT manifestations exhibited an unenhanced center and rim enhancement, with or without fine sand calcification and mottle calcification, or a LN with a spherical shape and minimal axial diameter (MAD) >10 mm (11) and an increase in size on follow-up CT; and v) a LN of spherical shape, peak standardized uptake value (SULpeak) >2.5 with a history of stimulated Tg level >10 ng/ml during thyroid hormone withdrawal. A total of 50 nodes were identified as mLNs.
18 F-FDG PET/CT. PET/CT imaging was performed using a Biograph 64 PET/CT scanner (Siemens AG, Munich, Germany). Prior to 18F-FDG PET/CT, all patients were instructed not to eat for ≥6 h to maintain their serum glucose levels at <11.1 mmol/l prior to injection. Image acquisition started ~1 h (mean, 56±2 min; range, 50-60 min) following intravenous injection of FDG (3.7 megabecquerel/kg). The lowest possible milliampere setting on the scanner was used to acquire the CT scans for attenuation correction. The whole-body CT imaging was performed from the skull to the upper part of the thigh with 120 kv, 0.5 sec rotation, 3 mm slice thickness and 0.8 mm intervals. The PET scans were obtained immediately following the whole-body CT scan, including 5-7 bed positions (1.5 min acquisition time per bed position) over the same range as the CT scan. Prior to PET/CT imaging, the serum thyrotropin (TSH) levels of patients were maintained at 30 mU/l.
I therapy and post-therapy
131 I whole-body scintigraphic imaging. Following radioiodine ablation of the residual normal thyroid tissue, 19 patients received a second dose of therapy and five also received an additional third dose of therapy. The TSH level was measured prior to 131 I administration and a minimum TSH of 30 mU/l was required.
131 I-NaI was orally administered, with activities ranging between 3.7 and 7.4 gigabecquerel (100-200 mCi). The 131 I WBS was conducted 3-4 days following 131 I administration, using a dual-head large-field γ camera with high energy collimators. An additional single-photon emission CT/CT (SPECT/CT) scan was performed with extensive cervical iodine accumulation on the WBS scan in four patients (4/32).
Imaging analysis. The acquired images were analyzed with Siemens True D (Syngo TrueD vE13A). The tracer uptake was expressed as a standardized uptake value, which was calculated according to the following formula: Measured activity concentration (Bq/ml) x body weight (g)/injected activity (Bq). To achieve a larger region of interest, the SULpeak that corrected for lean body mass was selected instead of the widely used single-pixel maximum standardized uptake value. The maximum standardized uptake has also been demonstrated to be subjected to upward bias in low-count studies compared with the SULpeak (12). All 18F-FDG PET/CT images and 131 I-WBS images were visually interpreted by two experienced nuclear physicians, and a final consensus was reached for all patients.
Statistical analysis. All quantitative data are expressed as the mean ± standard deviation. A χ 2 test and t-test were used to compare the SULpeak, minimum diameter, maximum diameter, LN zone, shape and density, punctate calcification, and the longitudinal and transverse ratios of the mLNs in the effective treatment group and ineffective treatment group. To assess the predictive role of SULpeak for the therapeutic effect, receiver operating characteristic (ROC) analysis was performed in both the effective treatment group and ineffective treatment group. The cut-off value was selected as 5.85, above which the best compromise between sensitivity and specificity could be achieved. Multivariate analysis of categorical variables was conducted using the survival analysis model. All statistical analysis was performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Patients. Among the 32 enrolled patients, the mean ± standard deviation age was 40.6±10.6 years (range, 24-58 years). According to the 7th Edition of The TNM staging system from The American Joint Committee on Cancer (13), 18 patients had stage I disease, 6 patients had stage II disease, 3 patients had stage III disease and 5 patients had stage Iv disease. During surgery, 13 patients were identified to have extrathyroidal extension and 18 patients had residual thyroid tissue on the initial 131 I WBS. In the present study, clinical serum outcomes of Tg were obtained under a TSH stimulated state <1 week prior to or following the PET/CT examination. Follow-up was performed ≥9 months following examination, with a mean follow-up time of 17.87±6.80 months (range, 9-36 months). I-WBS; ten were diagnosed by neck ultrasonography and 18 F-FDG PET with six lesions exhibiting a blurred margin, multiple microcalcifications, internal flow and peripheral flow, and four lesions exhibiting single microcalcification and extrathyroidal extension; and twelve lesions were diagnosed by CT and 18 F-FDG PET with seven lesions exhibiting a MAD >10 mm, and four lesions demonstrating an increase in size following ≥9 months. The characteristics of the mLNs are presented in Table I .
The metabolic response was determined separately for changes in the SULpeak based on the PET Response Criteria in Solid Tumors 1.0 (14) . A complete response (CR) was defined as a complete resolution of abnormal 18 F-FDG uptake within measurable target lesions, such that the uptake was equal to or less than the mean healthy-liver activity on the follow-up examination. A partial response (PR) was defined as a decrease of >30% in any baseline PET parameter. Progressive disease (PD) was defined as an increase in any baseline PET parameter by >30% between the baseline and follow-up, or by the appearance of a new 18 F-FDG-avid lesion. Stable disease (SD) was defined as non-PD, non-PR and non-CR. All mLNs were divided into the following two groups: An effective treatment group (group A) and an ineffective treatment group (group B). The lesions in group A achieved either CR or PR, while the lesions in the group B achieved either SD or PD.
The standard uptake value of lean body mass (SUL) of the 29 mLNs in group B (mean, 7.85±3.20; range, 3.00-16.60) was significantly higher compared with that of the 21 mLNs in group A (mean, 5.36±2.19; range, 2.60-12.80; P=0.027). A cut-off value of 5.85 was used to distinguish the ineffective treatment lesions from the mLNs receiving radioactive ablation based on the ROC curve analysis, with an area under the ROC curve (AUC) of 0.755. The accuracy of predicting the therapeutic effect of group A and group B was 76.19 and 72.4%, respectively (Fig. 1) . Furthermore, a significant difference was identified in the shape and density between the two groups (P=0.044; Table II ). However, the minimum diameter, Figure 1 . ROC curve of peak standardized uptake value to predict the therapeutic effect of lymph node metastasis (n=42). ROC, receiver operating characteristic. (Table III) . In this study, seven mLNs were found positive on both 131 I WBS and PET/CT image. During follow-up, it was identified that three LNs progressed into PD following radiotherapy, while the uptake of 131 I WBS decreased (Fig. 3 ) and four nodes in the SD group demonstrated no significant changes in 18F-FDG PET/CT and a decreased uptake on the 131 I-WBS (Fig. 4) . F-FDG PET/CT is useful for detecting the sites of metastatic disease and recurrence, which appear on radio-iodine images (17) . In the present study, all I on the initial WBS. Therefore, the present study attempted to use PET/CT imaging to predict the therapeutic effect of mLNs receiving 131 I radiotherapy. At present, the most widely used imaging technologies for diagnosis of thyroid cacinoma with mLNs include ultrasonography, magnetic resonance imaging (MRI), CT, SPECT and PET/CT (18) (19) (20) (21) (22) . Pathology is the gold standard for diagnosing LN metastasis of thyroid carcinoma (23) . However, certain mLNs are located deep in the neck, which presents difficulties for diagnosis. Imaging examination serves an important role in the diagnosis and therapeutic evaluation of thyroid cancer LN metastasis. Mulla and Schulte (24) reported that ultrasonography in the diagnosis of cervical LN metastases exhibits a sensitivity of 63% and specificity of 93%. However, ultrasonography possesses limitations for the diagnosis of central compartment lymph nodal metastases, as certain LNs are located in deep regions, the trachea and surrounding structures (25) .
131 I SPECT/CT has been used to evaluate patients with differentiated thyroid cancer (DTC); however, residual thyroid tissue following thyroidectomy affects the uptake of 131 I and imaging of mLNs (26) . Compared with CT, which provides low-resolution images for soft tissue, MRI exhibits distinct advantages for the diagnosis of metastatic thyroid carcinoma, including high-resolution determination of soft tissue, no radiation exposure and a multi-sequence, multi-parameter imaging capability (27) . For detection of cervical nodal metastasis in patients with DTC, MRI demonstrates a high sensitivity, accuracy, specificity and positive predictive value (19) ; however, MRI exhibits a low specificity and negative predictive value for the detection of lateral neck lymph nodal metastasis (28) . PET/CT is useful in localizing metastasis that does not accumulate iodine in patients with elevated Tg levels (29) and has been demonstrated to have a specificity ≤90% (30) . In the present study, mLNs were diagnosed by pathology, ultrasonography, CT, SPECT, PET/CT and clinical follow up. However, MRI was not analyzed in this study due to the limited number of patients examined.
The present study identified that the SULpeak of group A was significantly lower compared with that of group B prior to therapy. FDG is highly concentrated in cells with high glycolytic rates, including poorly differentiated, proliferating thyroid cancer cells (31) . The combination of a low iodine concentration and a high FDG concentration has been considered to be an indicator of poorly differentiated or dedifferentiated thyroid cancer cells (32) , which typically indicates a poor prognosis. Therefore, a low uptake of 18 The present results also demonstrated that a high SULpeak of mLNs and extrathyroidal extension following thyroid surgery were significant poor prognostic factors for patients receiving therapy. A number of previous studies have demonstrated that the 131 I WBS is negative for dedifferentiated PTC lesions that lack the ability to take up iodine and these dedifferentiated PTC lesions are 18 F-FDG-avid (32, 34, 35) . The present study identified that certain mLNs demonstrated positive results in both imaging examinations; however, the therapeutic effect of these mLNs has rarely been reported. In the present study, among the eight positive mLNs revealed by 131 I-WBS, two maintained SD, one achieved CR and the other five progressed to PD. A possible reason for this poor prognosis may be that the LN metastases had a lack of oxygen or were poorly differentiated, which reduced the effectiveness I accumulation was observed in two mLNs, which were negative on the first 131 I WBS and had SULpeaks, of 5.5 and 5.3, respectively on the PET/CT prior to therapy. Finally, both LNs achieved CR (Fig. 2) .
A number of previous studies have confirmed that macroscopic LN metastasis is a predictor that is specifically associated with PTC persistence or recurrence (36) (37) (38) (39) (40) . Wu et al (41) investigated prognostic factors of 131 I treatment for cervical LN metastases of PTC and suggested that the therapeutic effectiveness was associated with the size of the mLNs. However, the present results revealed that patients with a high SULpeak and a history of extrathyroidal extension exhibited a poorer therapeutic effect following 131 I ablation. mLNs with a SULpeak >5.85 could be considered as poor prognostic factors for therapy with or without a positive 131 I result. Furthermore, seven mLNs from 4 patients with PTC were both positive on 131 I WBS and PET/CT, which demonstrated no remission following 131 I therapy. These lesions may be associated with more aggressive characteristics and 131 I therapy appears to have little to no effect on the viability of such lesions (42) .
The present study had a number of limitations. Firstly, the number of subjects was small as only 50 mLNs were involved from 32 patients with PTC, which may lead to missing 131 I on SPECT imaging due to a low resolution. In addition, the pathological characteristics of the primary tumor and LNs were not completely analyzed due to the limited number of samples. Furthermore, the present study was retrospective in nature and excluded certain imaging methods that could additionally be performed, including ultrasound, CT and MRI. Therefore, future studies should aim to compare the predictive value of various imaging examinations for the prognosis of thyroid carcinoma with LN metastases.
In conclusion, a high SULpeak and spherical shape with a solid density of mLNs were identified as risk predictors for the clinical outcome of patients with PTC treated with radioiodine therapy, regardless of whether 131 I dose has accumulated on those nodes. When the SULpeak was >5.85, a poor therapeutic effect was revealed for mLNs. Therefore, patients with a high SULpeak of LNs and extrathyroidal extension may be considered to exhibit a poor prognosis. By introducing associated factors of mLNs on the predictive value of PET/CET, these may exhibit a useful role in the management of PTC. Further studies should focus on the detection of LNs with two positive images to identify the association between mLNs and the clinical outcome following 131 I therapy.
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